These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 2015597

  • 1. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes.
    Lamers HJ, Gratama JW, van Putten WL, Stoter G, Bolhuis RL.
    Cancer Res; 1991 May 01; 51(9):2324-8. PubMed ID: 2015597
    [Abstract] [Full Text] [Related]

  • 2. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 May 01; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 3. Immunotherapy with lymphokine-activated natural killer cells and recombinant interleukin-2: a feasibility trial in metastatic renal cell carcinoma.
    Hercend T, Farace F, Baume D, Charpentier F, Droz JP, Triebel F, Escudier B.
    J Biol Response Mod; 1990 Dec 01; 9(6):546-55. PubMed ID: 2074441
    [Abstract] [Full Text] [Related]

  • 4. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C, García-Pérez MJ, Ramirez R, Martín C, Alvarez MA, Martinez F, Gómez P, García-Castellano JM, Torres A.
    Bone Marrow Transplant; 1997 Mar 01; 19(6):545-51. PubMed ID: 9085733
    [Abstract] [Full Text] [Related]

  • 5. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells.
    Atzpodien J, Gulati SC.
    Stem Cells; 1993 Nov 01; 11(6):511-8. PubMed ID: 8111310
    [Abstract] [Full Text] [Related]

  • 6. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA, Pekle K, Gazzola MV, Collins NH, Bourhis JH, Gillio A.
    J Immunol; 1989 Nov 15; 143(10):3241-9. PubMed ID: 2809200
    [Abstract] [Full Text] [Related]

  • 7. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
    Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T.
    J Biol Response Mod; 1990 Apr 15; 9(2):167-77. PubMed ID: 1971303
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
    Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA.
    Cancer Res; 1988 Aug 01; 48(15):4409-16. PubMed ID: 3260537
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, Cairo MS.
    Exp Hematol; 2009 Oct 01; 37(10):1216-29. PubMed ID: 19638292
    [Abstract] [Full Text] [Related]

  • 13. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD, Economou JS, Shau H, Golub SH.
    J Surg Res; 1993 Nov 01; 55(5):486-92. PubMed ID: 8231167
    [Abstract] [Full Text] [Related]

  • 14. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy.
    Klasa RJ, Silver HK, Kong S.
    Cancer Res; 1990 Aug 15; 50(16):4906-10. PubMed ID: 2379154
    [Abstract] [Full Text] [Related]

  • 15. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA, Vujanovic NL, Herberman RB, Hiserodt JC.
    J Immunol; 1988 Apr 15; 140(8):2846-52. PubMed ID: 3258622
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 18. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
    Lin TH, Chu TM.
    Cancer Res; 1990 May 15; 50(10):3013-8. PubMed ID: 1970751
    [Abstract] [Full Text] [Related]

  • 19. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA, Custer MC, Rosenberg SA, Lotze MT.
    J Biol Response Mod; 1990 Apr 15; 9(2):113-26. PubMed ID: 2111373
    [Abstract] [Full Text] [Related]

  • 20. Requirement of thiol compounds as reducing agents for IL-2-mediated induction of LAK activity and proliferation of human NK cells.
    Yamauchi A, Bloom ET.
    J Immunol; 1993 Nov 15; 151(10):5535-44. PubMed ID: 8228244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.